Imminent U.S. launch of Wyost/Jubbonti (denosumab) with European launch in Q4 2025 2. Enzeevu/Afqlir (aflibercept) launch in Europe in Q4 2025 3. Tyruko (natalizumab) launch in the U.S. by the end of ...

Similarly, the company gave no definitive schedule for the U.S. rollout of Tyruko and Enzeevu. "This lack of a precise timing along with concerns related to tariffs should keep investors at bay for ...

Enzeevu/Afqlir (aflibercept) launch in Europe in Q4 2025 3. Tyruko (natalizumab) launch in the U.S. by the end of the year, pending FDA approval of JCV assay CEO Richard Saynor emphasized three key ...

Similarly, the company gave no definitive schedule for the U.S. rollout of Tyruko and Enzeevu. "This lack of a precise timing along with concerns related to tariffs should keep investors at bay ...

In 2024, the FDA approved biosimilar versions of Eylea, including the brand names Ahzantive, Enzeevu, Pavblu, Opuviz, and Yesafili. Anti-VEGF Treatments in the Pipeline In addition to injections, ...

In addition, there are now 5 aflibercept biosimilars approved in the US, 3 of which have been granted the interchangeability designation: Yesafili (Biocon Biologics) and Opuviz (Samsung Bioepis ...

The biosimilars Tyruko, Pyzchiva, Wyost, and Jubbonti are expected to hit the U.S. market in 2025, while Enzeevu is slated for a European launch in the fourth quarter of the year. Sandoz is confident ...